David Granville PhD, FAHA

Dr. Granville is a Professor in the Department of Pathology and Laboratory Medicine at the University of British Columbia (UBC). He recently moved his laboratory to the International Collaboration On Repair Discoveries (iCORD) and was appointed as the Associate Director of the BC Professional Firefighters’ Burn and Wound Healing Group, Department of Surgery, UBC. Dr. Granville’s research program over the past 20 years has been focused on mechanisms by which tissues are injured and identifying therapeutic targets that promote healing. In his early career (1994-2001), he worked at QLT Inc., where his research supported the development and approval of Visudyne® as the first treatment for age-related macular degeneration, the leading cause of blindness in the elderly. In 1999 Visudyne® was approved by the FDA resulting in the largest ophthalmic product release in history.